5Ortmann RA, Klippel JH. Update on cyclophosphamide for systemic lupus erythematosus. Rheum Dis Clin North Am, 2000,26: 363-375.
6McMurray RW. Nonstandard and adjunctive medical therapies for systemic lupus erythematosus. Arthritis Rheum, 2001, 45: 86-100.
7Guma M, Olive A, Roca J, et al. Association of systemic lupus erythematosus and hypermobility. Ann Rheun Dis, 2002, 61:1024-1026.
8Stoll T, Stucki G, Malik J, et al. Association of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index with measures of disease activity and health status in patients with systemic lupus erythematosus. J Rheumatol, 1997, 24: 309-313.
9Rapp CA, Berner B, Muller GA, et al.Long-term analysis of clinical disease activity and chronic organ damage in patients with systemic lupus erythematosus. Z Rheumatol, 2002, 61: 521-531.
10Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum, 1992, 35: 630-640.
